Table 2 Representative FDA-approved drugs or clinical trials of nanomedicine against HMs
Product name | Carrier | Drug | Status | Outcome or State | Identifier |
|---|---|---|---|---|---|
Leukemia | |||||
Marqibo kit | Liposome | Vincristine | Approved | Â | Â |
Vyxeos | Liposome | Ara-C, DOX | Approved | Â | Â |
Oncaspar | PEG | Pegaspargase | Approved | Â | Â |
MB-106 | Liposome | Annamycin | Phase 1 | 80% Overall Response Rate in Final Cohort of Phase 1 | NCT05319587 |
Lymphoma | |||||
2022–0453 | Liposome | MTX | Phase 2 | P2, Second Affiliated Hospital, School of Medicine, Zhejiang University N = 45, Recruiting | NCT05495100 |
MM | |||||
MCC-17814 | Liposome | DOX | Completed | P2, H. Lee Moffitt Cancer Center and Research Institute | NCT02186834 |
|  | Liposome | MTX | Phase 1 | P1, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. N = 60, Recruiting | NCT05052970 |
MDS | |||||
TLK199 HCl | Liposome | Ezatiostat, HCL | Phase 2 | P2, Telik, N = 65, Completed | NCT00035867 |
NCI-2018–01812 | Liposome | Ara-C, DOX | Phase 2 | P2, M.D. Anderson Cancer Center N = 50, Recruiting | NCT03672539 |
AEB1102 | PEG | Human arginase I | Phase 2 | P2, Aeglea Biotherapeutics, N = 29, Completed | NCT02732184 |